HEALTH CARE:
PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
Sarepta Therapeutics develops products for the treatment of life-threatening diseases, including cardiovascular disease, infectious disease and cancer. Its therapeutic products are principally based on NeuGene antisense technology.
Market Cap | 4.69 Billion | Shares Outstanding | 64.63 Million | Avg Volume | 3.299 Million |
1-Yr BETA vs S&P TR | Current Ratio | 13.91 | Quick Ratio | 12.96 |
Q3 2019 | All Institutions | Hedge Funds 1 |
---|---|---|
To trade SRPT now: | |
|
Filers who had this stock in their top 10: | 6 | 6 (0.63%) |
13F Filers holding this stock: | 322 | 46 (4.81%) |
Aggregate 13F shares on 09/30/2019: | 70.538 Million | 12.718 Million |
Aggregate 13F shares on 06/30/2019: | 70.597 Million | 10.422 Million |
Percent change: | -0.08% | 22.03% |
Funds creating new positions: | 70 | 15 |
Funds Adding to an existing position: | 119 | 20 |
Funds closing out their position: | 90 | 28 |
Funds reducing their position: | 99 | 9 |
1 hedge funds as identified by whalewisdom.com through public filings. |
View recent insider trading info
Sarepta Therapeutics Inc Chart by YCharts
Please sign in first
none
25 Thousand total shares from 3 transactions
34.3 Thousand total shares from 7 transactions
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
HOWTON DAVID T EVP, GENERAL COUNSEL |
|
25,171 | 2019-11-22 | 4 |
|
0 | 2019-11-20 | 0 | |
|
0 | 2019-11-20 | 2 | |
|
0 | 2019-11-18 | 2 | |
|
62,500 | 2019-09-18 | 2 | |
|
3,187,065 | 2019-09-12 | 5 | |
MAHATME SANDESH EVP, CFO & CBO |
|
42,191 | 2019-08-21 | 7 |
INGRAM DOUGLAS S PRESIDENT & CEO |
|
432,197 | 2019-08-12 | 1 |
|
0 | 2019-08-08 | 0 | |
|
7,355 | 2019-07-19 | 3 | |
|
0 | 2019-06-18 | 0 | |
|
0 | 2019-06-11 | 3 | |
|
0 | 2019-06-06 | 0 | |
|
0 | 2019-05-29 | 0 | |
|
11,717 | 2019-05-23 | 2 | |
O'NEILL GILMORE NEIL EVP, R&D & CMO |
|
7,370 | 2019-05-23 | 2 |
|
7,051 | 2019-03-04 | 1 | |
O'NEILL GILMORE NEIL EVP, R&D & CMO O'NEILL GILMORE NEIL EVP, R&D & CMO |
|
0 | 2019-03-04 | 2 |
JACOBSEN MICHAEL A VP FINANCE AND CAO |
|
0 | 2019-02-08 | 0 |
APHALE JAYANT SEE REMARKS |
|
0 | 2018-09-27 | 0 |
RUFF SHAMIM SVP, CHIEF REGULATORY AFFAIRS |
|
31,936 | 2018-05-22 | 0 |
|
0 | 2018-05-09 | 0 | |
BASI GURIQBAL S. SVP, CHIEF SCIENTIFIC OFFICER |
|
0 | 2018-03-05 | 0 |
KRESS JEAN-PAUL EVP PRES INT'L & GLOBAL HD GTO |
|
0 | 2017-07-03 | 0 |
STEHMAN-BREEN CATHERINE SVP, CHIEF MEDICAL OFFICER |
|
0 | 2017-04-03 | 0 |
WOOD JOAN VP, HUMAN RESOURCES |
|
14,926 | 2016-09-20 | 0 |
SHREWSBURY STEPHEN B CMO; SENIOR VP CLINICAL DEV. |
|
0 | 2016-03-10 | 0 |
|
8,166 | 2016-02-29 | 0 | |
|
0 | 2015-07-30 | 0 | |
|
6,333 | 2015-02-27 | 0 | |
CHRISTOPHER NISHAN GARABEDIAN PRESIDENT AND CEO |
|
29,552 | 2015-02-27 | 0 |
KRIEG ARTHUR M SVP, CHIEF SCIENTIFIC OFFICER |
|
0 | 2014-01-13 | 0 |
|
0 | 2013-06-04 | 0 | |
BOYLE J DAVID II SENIOR VP AND CFO |
|
0 | 2012-01-04 | 0 |
TOSHAV BRACHA EPHRAT SR VP & GENERAL COUNSEL |
|
0 | 2011-08-31 | 0 |
MILE MELINDA G CONTROLLER AND PAO |
|
0 | 2011-08-31 | 0 |
LINSLEY PETER S SVP & CHIEF SCIENTIFIC OFFICER |
|
0 | 2011-05-16 | 0 |
IVERSEN PATRICK L SR VP OF RESEARCH & DEVLOPMENT |
|
0 | 2010-08-23 | 0 |
WELLER DWIGHT D SR. VP CHEMISTRY & MFG. |
|
0 | 2010-08-23 | 0 |
MEDEIROS PAUL SVP BUSINESS DEVELOPMENT |
|
0 | 2010-08-23 | 0 |
JOHNSON GRAHAM SR VP PRECLINICAL DEV & RSRCH |
|
0 | 2010-08-23 | 0 |
HUDSON LESLIE FORMER CEO |
|
384,559 | 2010-07-30 | 0 |
|
No longer subject to file | 2010-05-10 | 0 | |
|
2,935,696 | 2010-03-16 | 0 | |
HAYWOOD CHERYL |
|
8,329,126 | 2010-03-16 | 0 |
KOLE RYSZARD SVP/DISCOVERY RESEARCH |
|
1,862,926 | 2010-02-09 | 0 |
|
7,971,542 | 2009-09-28 | 0 | |
FORREST K MICHAEL OUTSIDE DIRECTOR |
|
15,000 | 2009-05-19 | 0 |
FARA JOHN W PHD |
|
500 | 2008-05-20 | 0 |
OHANLEY PETER D SR. VICE PRESIDENT |
|
0 | 2008-02-28 | 0 |
|
15,446 | 2008-02-02 | 0 |
Reporting Owners | Transaction Date | Transaction Code | Shares | Share Price | Acquired or Disposed | Shares Owned Following Transaction | Combined shares owned after filing | Direct/Indirect Ownership | 10b-5 |
---|---|---|---|---|---|---|---|---|---|
2019-11-22 | M | 5,590 | d | 0 | 25,171.00 | direct | |||
2019-11-22 | M | 8,580 | d | 18,579 | 25,171.00 | direct | yes | ||
2019-11-22 | F | 2,804 | $107.02 | d | 25,171 | 25,171.00 | direct | ||
2019-11-22 | M | 52 | $13.71 | a | 14,485 | 25,171.00 | direct | ||
2019-11-22 | S | 3,753 | $105.00 | d | 14,950 | 25,171.00 | direct | yes | |
2019-11-22 | M | 4,025 | $13.71 | a | 28,413 | 25,171.00 | direct | yes | |
2019-11-22 | M | 52 | d | 18 | 25,171.00 | direct | |||
2019-11-22 | M | 4,025 | d | 1,858 | 25,171.00 | direct | yes | ||
2019-11-22 | M | 7,900 | $23.85 | a | 27,975 | 25,171.00 | direct | ||
2019-11-22 | M | 2,440 | $13.71 | a | 14,433 | 25,171.00 | direct | ||
2019-11-22 | S | 18,290 | $105.00 | d | 18,703 | 25,171.00 | direct | yes | |
2019-11-22 | M | 5,685 | $13.71 | a | 24,388 | 25,171.00 | direct | yes | |
2019-11-22 | M | 7,900 | d | 5,118 | 25,171.00 | direct | |||
2019-11-22 | M | 2,440 | d | 2,470 | 25,171.00 | direct | |||
2019-11-22 | M | 5,685 | d | 1,280 | 25,171.00 | direct | yes | ||
2019-11-22 | M | 5,590 | $13.90 | a | 20,075 | 25,171.00 | direct | ||
2019-11-22 | S | 2,957 | $105.00 | d | 11,993 | 25,171.00 | direct | yes | |
2019-11-22 | M | 8,580 | $13.90 | a | 36,993 | 25,171.00 | direct | yes | |
2019-11-18 | A | 80,000 | a | 80,000 | 0.00 | direct |